16-Jun-2008
Financial Express
The Daiichi Sankyo-Ranbaxy Laboratories deal has come as a shot in the arm for India’s Comprehensive Economic Co-operation Agreement (CECA) negotiations with Japan. Indian pharma companies have been unable to break into Japan, the world’s second largest drug market, due to the country’s stringent sanitary and phytosanitary standards, technical barriers to trade (TBT) and environmental norms.
12-Mar-2008
Economic Times
The Indian government has asked industry to come up with an ‘offensive’ list of items of export interest to India in the Japanese market.
27-Aug-2007
IntelliBriefs
India is prime "real estate" for Japan, both in economic and defense terms. Most importantly, India is a large consumer market with the potential to increase profits for Japanese corporations.